Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
KENSINGTON, Md. and SHORASHIM, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which, in animal models caused sustained prevention of misfolded amyloid beta molecules from aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. The presentation also included positive safety and tolerability data from the company’s Phase 1 study in both healthy and glaucoma patients. These data were presented at the Glaucoma 360 conference on February 1, 2019 in San Francisco by the company’s chief scientific officer, Hermann Russ, M.D., Ph.D.
“Misfolded monomers of amyloid beta have been shown to rapidly form toxic oligomers that play a significant role in the advancement of ophthalmic diseases, including glaucoma and dry age-related macular degeneration (dry AMD). The unique mechanism of action of GAL-101 has been shown to prevent this advancement and instead, form amorphous assemblies, or blobs, that are benign in the eye,” commented Dr. Russ. “These preclinical data, combined with a positive result in the Phase 1 study have made it possible for us to develop a Phase 2 program, for which we are currently in the planning and fundraising stage.”
In preclinical data, GAL-101 was shown to reach the retina with a greater than 30-fold therapeutic threshold within 5 minutes of eye drop application, and lasting for multiple hours, into sustained effect for weeks. Furthermore, the data showed more than 90 percent survival of retinal ganglion cells compared to controls (p<0.05), with the experiment being repeated multiple times. In addition, the company conducted Phase 1 trials demonstrating safety and tolerability in both health subjects (n=40) and glaucoma patients (n=30).
MRZ-99030 is a proprietary compound designed to prevent the formation of all forms of toxic amyloid beta oligomers, by binding with high affinity to the misfolded amyloid beta monomers before they can form toxic soluble oligomers. These then rapidly conglomerate into amorphous, non-beta-sheet formations, which we call “blobs.” These “blobs” are innocuous. Interestingly, once formed, the “blobs” have shown the capacity to collect additional misfolded amyloid beta monomers even in the absence of additional MRZ-99030 molecules, through a self-propagation mechanism. This novel “trigger effect,” protected by Galimedix’ patent portfolio, results in a sustained action effect lasting far longer than the time a single administration of the drug remains at therapeutic levels in the retina, potentially allowing for a convenient sustained inter-treatment interval application regimen for patients. Thus MRZ-99030 eye drops may potentially provide sustained prevention of formation of toxic amyloid beta oligomers, clearing the system of these pathological factors, which has been shown in animal studies to lead to gradual removal of toxic beta amyloid deposits, and which the current “Hot Topic” poster has shown could potentially reduce neural deficit and improve function.
Based in the United States and Israel, Galimedix is a phase 2 ophthalmic pharmaceutical company with a novel, patented small molecule drug with a novel MOA addressing glaucoma and dry AMD utilizing an eye drops delivery platform, which may offer significant safety and compliance advantages over commonly used direct ocular injections. Eye drops are often used to deliver steroids and other small molecules, like GAL-101, in retinal disease, and studies with Galimedix’ eye drops in monkeys have demonstrated more than 30 times predicted therapeutic levels quickly reaching the retina of the closest model to humans. Compelling efficacy data from GAL-101 eye drops in relevant animal models have demonstrated more than 90 percent neuroprotection, and the compound is supported by several leading experts in glaucoma and in dry AMD who also support the design of the company’s proposed phase 2 studies.
Galimedix has exclusive worldwide license from Tel Aviv University, following return of license by a German pharma (Merz) due to management change and strategic pivot away from neuroscience. In the meantime, key members of the Merz Pharma team that developed the compound are now working with or for the company. The license also includes a next generation, potentially superior version, intended for oral delivery, with potential to treat retinal and other CNS diseases.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
All Regulatory Clearances for Saxo Bank and BinckBank obtained to close the Offer23.7.2019 18:20:00 CEST | Press release
This is a joint press release by BinckBank N.V. (BinckBank), Star Bidco B.V. (the Offeror) and Saxo Bank A/S (Saxo Bank, pursuant to Section 4, paragraph 3 of the Dutch decree on public takeover bids (Besluit openbare biedingen Wft) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary and priority shares in the capital of BinckBank (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the Offer Memorandum dated 12 March 2019 (the Offer Memorandum). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States or Canada or in any other jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum. All Regulatory Cleara
Golar LNG Partners LP Cash Distributions23.7.2019 18:13:00 CEST | Press release
Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended June 30, 2019 of $0.4042 per common and general partner unit. This cash distribution will be paid on August 14, 2019 to all common and general partner unitholders of record as of the close of business on August 7, 2019. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from May 15, 2019 through August 14, 2019 has also been declared. This will be payable on August 15, 2019 to all Series A preferred unitholders of record as at August 8, 2019. Golar LNG Partners LP Hamilton, Bermuda July 23, 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
EUROCOMMERCIAL PROPERTIES N.V. TRANSACTIONS BUYBACK PROGRAMME23.7.2019 18:05:00 CEST | Press release
Date: 23 July 2019 Release: After close of business Euronext Please open the following link to read the full report including annexes: Attachment Full press release
ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS23.7.2019 18:00:00 CEST | Press release
Almere, The Netherlands July 23, 2019, 6 p.m. CET ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2019 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2018 Q1 2019 Q2 2019 New orders 175.9 235.0 373.1 Net sales 208.7 248.8 363.3 Gross profit margin % 42.1 % 41.3 % 59.0 % Operating result 38.3 47.0 150.2 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 21.6 3.1 2.0 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.0 ) (3.4 ) (3.4 ) Net earnings 59.4 49.4 121.6 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 62.4 52.8 125.0 • New orders were €373 million. Excluding €103 million related to the patent litigation settlement new orders were €270 million. • Net
Banks net position in the Riksbank23.7.2019 16:40:00 CEST | Press release
Jul 23, 2019 SEK MILLION LENDING BORROWING 271
TGS and EnergyIQ Announce Collaboration to Launch EIQ TGS Data Loader23.7.2019 15:00:00 CEST | Press release
Houston, Texas (July 23, 2018) – TGS, a leading provider of multi-client geoscience and engineering data for Exploration & Production companies, today announced the EIQ TGS Data Loader, developed in collaboration with EnergyIQ. Now, companies can automatically blend industry leading data with proprietary customer data in an enterprise well master data management platform for advanced analysis and decision making. The EIQ TGS Loader processes the most up-to-date and complete data by automatically accessing and processing TGS web services. This data is matched, validated and blended with other proprietary and third-party sources within a PPDM gold compliant data model to create the most trusted version all available data in a single repository. The data is then provided in a 10/12/14 digit format for consumption by enterprise, interpretation, and analytics applications. Carl Neuhaus, Vice President - Well Data Products of TGS, said, “We are excited to partner with EnergyIQ to make access